Glucotrack, Inc., a medical device company focused on the design, development, and commercialisation of novel technologies for people with diabetes, announced that Usman Latif, MD, MBA, has been named to Glucotrack’s clinical advisory team, providing strategic counsel as the Company advances its epidural glucose monitoring applications alongside its continuous blood glucose monitor (CBGM).

“Dr Latif is a prominent pain management specialist and opinion leader with deep expertise in neuromodulation and treatment of Painful Diabetic Neuropathy (PDN). His exceptional knowledge in pain management and product design will be invaluable as we advance integrated disease and device management solutions for PDN patients,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack.

Dr Latif is an Associate Professor in the Department of Anesthesiology, Pain and Perioperative Medicine at The University of Kansas Medical Centre and a Board-certified Anesthesiologist at The University of Kansas Health System. Dr Latif earned his medical degree from the University of Kansas and completed residencies in Internal Medicine at Wake Forest University and Anesthesiology at Johns Hopkins Hospital. He then completed a fellowship in Interventional Pain Management at Harvard/Massachusetts General Hospital. He previously served as faculty at Yale University School of Medicine, where he worked as a Sub-Investigator at the Pfizer Clinical Research Unit. Dr Latif also holds an MBA and earned a certificate in Value-Based Healthcare from Harvard Business School. He has published extensively in novel research, clinical guidelines, and textbook chapters. His research focuses on neuromodulation, innovative technology applications, AI, and data-driven medical advances.